8-K: Neogen Corporation Updates Investors on Petrifilm Production Transition

Neogen Corporation provides an update on its Petrifilm product line, including the transition of manufacturing to a new facility in Lansing, Michigan.

Summary

• Neogen Corporation hosted investors on April 22, 2025, to discuss its Petrifilm product line.
• The company is transitioning Petrifilm production to a new state-of-the-art facility in Lansing, Michigan.
• The transition involves moving production from a third-party manufacturing partner, with equipment mirroring that used in Poland.
• Key manufacturing engineers from the Poland setup are now Neogen employees, guiding the project.
• Neogen aims to ensure continuous Petrifilm supply during the transition.
• The new facility is expected to begin test production in the fall of 2025.
• The company expects over $100M in net proceeds from the Cleaners & Disinfectants divestiture, which will be used to repay $100M drawn on the revolver.
• The Cleaners & Disinfectants transaction represents a trailing EBITDA multiple of approximately 12x after addressing stranded costs.
• Restructuring actions implemented in Q2 FY25 are expected to result in FY26 Genomics EBITDA being roughly equivalent to FY25.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. Neogen is making strategic investments in its Petrifilm production and divesting non-core assets to strengthen its financial position. However, there are also risks associated with the manufacturing transition and potential tariff impacts.

Positives

• The new Petrifilm manufacturing facility in Lansing, Michigan, will ensure a stable and reliable supply of Petrifilm.
• Using the same equipment and key personnel from the Poland facility should maintain consistent product quality.
• The Cleaners & Disinfectants divestiture provides over $100M to repay debt.
• Petrifilm plates offer environmental benefits, including 76% less energy, 75% less CHG emissions, 79% less water, and 66% less waste compared to traditional agar plates.
• Petrifilm plates enhance productivity by 48% on average and require up to 85% less space than agar.

Negatives

• The transition of Petrifilm production could pose risks to supply if not managed effectively.
• The largest potential tariff impact is in the Animal Safety segment.

Risks

• The successful implementation of the CEO succession plan is a risk factor.
• The continued integration of the 3M food safety business and the realization of expected benefits are subject to risks.
• The relationship with and performance of the transition manufacturing partner is a risk.
• The company's ability to adequately and timely remediate certain identified material weaknesses in its internal control over financial reporting is a risk.
• Competition, recruitment and retention of key employees, and the impact of weather on agriculture and food production are ongoing risks.
• Global business disruption caused by the Russia invasion in Ukraine and related sanctions, and the conflict in the Middle East pose risks.
• The effect of tariffs, identification and integration of acquisitions, research and development risks, and intellectual property protection are also risks.
• Increasing and developing government regulation is a risk.

Future Outlook

Neogen is focused on ensuring a stable and reliable supply of Petrifilm through the transition to its new manufacturing facility and is taking steps to mitigate potential tariff impacts and optimize its Genomics business.

Management Comments

• Neogen understands the importance of Petrifilm to customers and the industry, and is making investments to ensure the operations deliver stable, reliable supply well into the future.

Industry Context

The announcement highlights Neogen's commitment to its Petrifilm product line, a key offering in the food safety testing market. The company's investment in a new manufacturing facility demonstrates its focus on maintaining a competitive edge and ensuring supply chain stability.

Comparison to Industry Standards

• Neogen's investment in a state-of-the-art Petrifilm production facility mirrors the strategies of other major players in the food safety diagnostics industry, such as 3M (prior to divesting the business to Neogen) and bioMérieux, who also maintain advanced manufacturing capabilities to ensure product quality and supply chain resilience.
• The reported trailing EBITDA multiple of ~12x for the Cleaners & Disinfectants divestiture is within the typical range for transactions in the specialty chemicals and diagnostics sectors, suggesting a fair valuation for the divested business.
• The focus on bovine genomics aligns with industry trends towards precision agriculture and animal health, where companies like Zoetis and Illumina are also investing in genomic solutions for livestock management.

Stakeholder Impact

• Shareholders: The transition of Petrifilm production and the divestiture of the Cleaners & Disinfectants business could impact shareholder value.
• Customers: Ensuring a stable and reliable supply of Petrifilm is crucial for maintaining customer satisfaction.
• Employees: The transition of manufacturing and restructuring actions could affect employees.

Next Steps

• Continue installation of the second production line in Q1 FY26.
• Complete product validation on a SKU-by-SKU basis.
• Transition production to the Lansing facility.

Key Dates

Keywords

Petrifilm, Manufacturing, Neogen, Production, Transition, Facility, Food Safety, Genomics, EBITDA, Divestiture